Cel The GARDair project will optimize and validate the first predictive assay for respiratory sensitization and bring it to market. This innovative in vitro test builds on the successes of its forerunner – the GARDskin assay, which has been shown to hold the highest predictive power (89%) of skin sensitizers amongst all commercially available methods. The GARD technology offers an unparalleled way to make hazard predictions, as it uses a human dendritic cell line to monitor immunological responses to chemical exposure. This approach offers not only higher predictive accuracy than in vivo tests, but also eliminates the need for animal testing at the same time as it cuts costs and experimental time.The need for ethical, accurate and economical safety assessment procedures is growing in parallel with the amount of new chemicals introduced yearly into our environment by the pharma, cosmetics and chemical industries. In order to protect both workers and customers from chemically induced sensitization, EU legislation dictates that all chemicals must be sensitization tested within the next two decades. The EC and ECVAM have a leading role within the OECD to develop test guidelines for skin sensitization hazard identification. Similar steps have not yet been taken in the area of respiratory sensitization due to the lack of available test methods to identify such compounds. The GARDair assay thus holds the power to drive the EU regulatory framework by entering a globally uncontested market space. If successful, the project will allow SenzaGen to become a key player in any application of animal-free, cell-based systems, aiming to assess sensitization capabilities of various compounds and to fully realize its business development strategy. Dziedzina nauki medical and health sciencesmedical biotechnologysocial scienceseconomics and businessbusiness and managementcommerce Program(-y) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Temat(-y) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Zaproszenie do składania wniosków H2020-SMEInst-2016-2017 Zobacz inne projekty w ramach tego zaproszenia Szczegółowe działanie H2020-SMEINST-2-2016-2017 System finansowania SME-2 - SME instrument phase 2 Koordynator SENZAGEN AB Wkład UE netto € 2 421 800,00 Adres MEDICON VILLAGE 406 SCHEELEVAGEN 2 223 81 LUND Szwecja Zobacz na mapie MŚP Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant. Tak Region Södra Sverige Sydsverige Skåne län Rodzaj działalności Private for-profit entities (excluding Higher or Secondary Education Establishments) Linki Kontakt z organizacją Opens in new window Uczestnictwo w unijnych programach w zakresie badań i innowacji Opens in new window sieć współpracy HORIZON Opens in new window Koszt całkowity € 2 421 800,00